1911 related articles for article (PubMed ID: 21741092)
21. Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study.
Klimek L; Schendzielorz P; Pinol R; Pfaar O
Clin Exp Allergy; 2012 Jun; 42(6):936-45. PubMed ID: 22909165
[TBL] [Abstract][Full Text] [Related]
22. Clinical efficacy of microencapsulated timothy grass pollen extract in grass-allergic individuals.
TePas EC; Hoyte EG; McIntire JJ; Umetsu DT
Ann Allergy Asthma Immunol; 2004 Jan; 92(1):25-31. PubMed ID: 14756461
[TBL] [Abstract][Full Text] [Related]
23. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study.
Senti G; von Moos S; Tay F; Graf N; Sonderegger T; Johansen P; Kündig TM
J Allergy Clin Immunol; 2012 Jan; 129(1):128-35. PubMed ID: 21996342
[TBL] [Abstract][Full Text] [Related]
24. [Specific skin reactions induced by individual pollen preparations in hypersensitivity persons].
Paranos S; Petrović S; Vojović I
Srp Arh Celok Lek; 1998; 126(9-10):362-7. PubMed ID: 9863408
[TBL] [Abstract][Full Text] [Related]
25. Immunoglobulin E and G antibody profiles to grass pollen allergens during a short course of sublingual immunotherapy.
Aberer W; Hawranek T; Reider N; Schuster C; Sturm G; Kränke B
J Investig Allergol Clin Immunol; 2007; 17(3):131-6. PubMed ID: 17583098
[TBL] [Abstract][Full Text] [Related]
26. Double-blind, placebo-controlled evaluation of grass pollen specific immunotherapy with oral drops administered sublingually or supralingually.
Panzner P; Petrás M; Sýkora T; Lesná I
Respir Med; 2008 Sep; 102(9):1296-304. PubMed ID: 18585908
[TBL] [Abstract][Full Text] [Related]
27. The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis.
Keskin O; Tuncer A; Adalioglu G; Sekerel BE; Saçkesen C; Kalayci O
Pediatr Allergy Immunol; 2006 Sep; 17(6):396-407. PubMed ID: 16925684
[TBL] [Abstract][Full Text] [Related]
28. Agreement of efficacy assessments for five-grass pollen sublingual tablet immunotherapy.
Didier A; Melac M; Montagut A; Lhéritier-Barrand M; Tabar A; Worm M
Allergy; 2009 Jan; 64(1):166-71. PubMed ID: 19076546
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients.
Rossi RE; Monasterolo G
Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study.
Ott H; Sieber J; Brehler R; Fölster-Holst R; Kapp A; Klimek L; Pfaar O; Merk H
Allergy; 2009 Jan; 64(1):179-86. PubMed ID: 19076534
[TBL] [Abstract][Full Text] [Related]
31. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: S2k Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Society for Pediatric Allergy and Environmental Medicine (GPA), the Medical Association of German Allergologists (AeDA), the Austrian Society for Allergy and Immunology (ÖGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German Association of ENT Surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal Association of Pulmonologists (BDP) and the German Dermatologists Association (BVDD).
Pfaar O; Bachert C; Bufe A; Buhl R; Ebner C; Eng P; Friedrichs F; Fuchs T; Hamelmann E; Hartwig-Bade D; Hering T; Huttegger I; Jung K; Klimek L; Kopp MV; Merk H; Rabe U; Saloga J; Schmid-Grendelmeier P; Schuster A; Schwerk N; Sitter H; Umpfenbach U; Wedi B; Wöhrl S; Worm M; Kleine-Tebbe J; Kaul S; Schwalfenberg A
Allergo J Int; 2014; 23(8):282-319. PubMed ID: 26120539
[TBL] [Abstract][Full Text] [Related]
32. Tolerability of the SQ Tree SLIT Tablet in Adults.
Birk AO; Andersen JS; Villesen HH; Steffensen MA; Calderon MA
Clin Ther; 2017 Sep; 39(9):1858-1867. PubMed ID: 28844318
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis.
Frew AJ; Powell RJ; Corrigan CJ; Durham SR;
J Allergy Clin Immunol; 2006 Feb; 117(2):319-25. PubMed ID: 16461133
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and tolerability of high dose sublingual immunotherapy in patients with rhinoconjunctivitis.
Worm M
Eur Ann Allergy Clin Immunol; 2006 Dec; 38(10):355-60. PubMed ID: 17274520
[TBL] [Abstract][Full Text] [Related]
35. Safety of ragweed sublingual allergy immunotherapy tablets in adults with allergic rhinoconjunctivitis.
Nayak AS; Atiee GJ; Dige E; Maloney J; Nolte H
Allergy Asthma Proc; 2012; 33(5):404-10. PubMed ID: 23026182
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of a compliance device in a subgroup of adult patients receiving specific immunotherapy with grass allergen tablets (GRAZAX) in a randomized, open-label, controlled study: an a priori subgroup analysis.
Jansen A; Andersen KF; Brüning H
Clin Ther; 2009 Feb; 31(2):321-7. PubMed ID: 19302904
[TBL] [Abstract][Full Text] [Related]
37. Grass allergen tablet immunotherapy relieves individual seasonal eye and nasal symptoms, including nasal blockage.
Durham SR; Riis B
Allergy; 2007 Aug; 62(8):954-7. PubMed ID: 17620075
[TBL] [Abstract][Full Text] [Related]
38. High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: a double-blind, placebo-controlled study.
Wahn U; Klimek L; Ploszczuk A; Adelt T; Sandner B; Trebas-Pietras E; Eberle P; Bufe A;
J Allergy Clin Immunol; 2012 Oct; 130(4):886-93.e5. PubMed ID: 22939758
[TBL] [Abstract][Full Text] [Related]
39. Effect of AIT in children including potential to prevent the development of asthma.
Valovirta E
Allergy; 2011 Jul; 66 Suppl 95():53-4. PubMed ID: 21668856
[TBL] [Abstract][Full Text] [Related]
40. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet.
Durham SR; Emminger W; Kapp A; Colombo G; de Monchy JG; Rak S; Scadding GK; Andersen JS; Riis B; Dahl R
J Allergy Clin Immunol; 2010 Jan; 125(1):131-8.e1-7. PubMed ID: 20109743
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
